Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Current Oncology Reports
Erschienen in:

11.09.2024 | REVIEW

Developing a National Study That Integrates the Geriatric Assessment into the Care of Older Patients with Myeloid Malignancies

verfasst von: Vijaya Raj Bhatt

Erschienen in: Current Oncology Reports | Ausgabe 11/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

To highlight the priorities in geriatric assessment research in myeloid malignancies and discuss design considerations necessary to ensure research is patient-centric, generalizeable, and high quality.

Recent Findings

Older adults with myeloid malignancies including those who are perceived to have excellent performance status have multiple functional impairments. These impairments are associated with early mortality. Older adults have different functional trajectories through the course of treatment; this will be further investigated in our ongoing multicenter study. In a single-center study, we have demonstrated the use of geriatric assessment to guide treatment is feasible.

Summary

Key priorities include designing a multicenter validation study to confirm the role of geriatric assessment in determining treatment tolerance and survival. Such a study should include core geriatric assessment measures and should enroll diverse patient population across various practices. Conducting such a study is necessary to advance patient care and trial design, and to open venues to conduct studies to confirm the role of geriatric assessment in treatment selection.
Literatur
1.
Bhatt VR, Wichman C, Al-Kadhimi ZS, Koll TT, Fisher AL, Mahato RI, et al. Integrating geriatric assessment and genetic profiling to personalize therapy selection in older adults with acute myeloid leukemia. J Geriatr Oncol. 2022;13(6):871–4.CrossRefPubMedPubMedCentral
2.
Min G-J, Cho B-S, Park S-S, Park S, Jeon Y-W, Shin S-H, et al. Geriatric assessment predicts nonfatal toxicities and survival for intensively treated older adults with AML. Blood. 2022;139(11):1646–58.CrossRefPubMed
3.
Ritchie EK, Klepin HD, Storrick E, Major B, Le-Rademacher J, Wadleigh M, et al. Geriatric assessment for older adults receiving less-intensive therapy for acute myeloid leukemia: report of CALGB 361101. Blood Adv. 2022;6(12):3812–20.CrossRefPubMedPubMedCentral
4.
Klepin HD, Geiger AM, Tooze JA, Kritchevsky SB, Williamson JD, Pardee TS, et al. Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. Blood. 2013;121(21):4287–94.CrossRefPubMedPubMedCentral
5.
Hupfer V, Grishina O, Schmoor C, Schlenk RF, Salih HR, Crysandt M, et al. Validation of a frailty score predicting survival of elderly, non-Fit AML patients receiving hypomethylating therapy: results of the decider trial. Blood. 2018;132(Suppl 1):720.CrossRef
6.
Saad M, Loh KP, Tooze JA, Pardee TS, Ellis LR, Powell BL, et al. Geriatric assessment and survival among older adults receiving postremission therapy for acute myeloid leukemia. Blood. 2020;136(23):2715–9.CrossRefPubMedPubMedCentral
7.
Klepin HD, Geiger AM, Tooze JA, Kritchevsky SB, Williamson JD, Ellis LR, et al. The feasibility of inpatient geriatric assessment for older adults receiving induction chemotherapy for acute myelogenous leukemia. J Am Geriatr Soc. 2011;59(10):1837–46.CrossRefPubMedPubMedCentral
8.
Bhatt VR. Advances and unanswered questions in management of acute myeloid leukemia in older adults: a glimpse into the future. J Geriatr Oncol. 2021;12(6):980–4.CrossRefPubMedPubMedCentral
9.
Bhatt VR. Understanding patients’ values and priorities in selecting cancer treatments: developing a therapy preference scale. J Geriatr Oncol. 2019;10(5):677–9.CrossRefPubMed
10.
Richardson DR, Crossnohere NL, Seo J, Estey E, O’Donoghue B, Smith BD, et al. Age at diagnosis and patient preferences for treatment outcomes in AML: a discrete choice experiment to explore meaningful benefits. Cancer Epidemiol Biomarkers Prev. 2020;29(5):942–8.CrossRefPubMedPubMedCentral
11.
Bhatt VR, Dhakal P, Wichman CS, Pozehl B. Development and validation of the therapy preference scale to understand patients systemic cancer treatment preferences. Future Oncol. 2021;17(1):37–44.CrossRefPubMed
12.
Dhakal P, Wichman CS, Pozehl B, Weaver M, Fisher AL, Vose J, et al. Preferences of adults with cancer for systemic cancer treatment: do preferences differ based on age? Future Oncol. 2022;18(3):311–21.CrossRefPubMed
13.
Dhakal P, Wichman C, Pozehl B, Mahato K, Bhatt VR. Preferences of patients with acute myeloid leukemia and other myeloid malignancies on cancer treatment: effect of patient- and treatment-characteristics? Blood. 2023;142(Supplement 1):3731.CrossRef
14.
Bhatt VR, Shostrom V, Gundabolu K, Armitage JO. Utilization of initial chemotherapy for newly diagnosed acute myeloid leukemia in the United States. Blood Adv. 2018;2(11):1277–82.CrossRefPubMedPubMedCentral
15.
Bhatt VR, Wichman C, Koll TT, Fisher A, Wildes TM, Haddadin M, et al. Use of geriatric assessment and genetic profiling to personalize selection of intensive versus low intensity chemotherapy in older adults with acute myeloid leukemia (AML): final results of a phase II trial. Blood. 2023;142(1):4265.CrossRef
16.
Bhatt VR. Personalizing therapy for older adults with acute myeloid leukemia: role of geriatric assessment and genetic profiling. Cancer Treat Rev. 2019;75:52–61.CrossRefPubMed
17.
Artz A, Logan BR, Saber W, Geller N, Bellach A, Kou J, et al. The composite health risk assessment model (CHARM) to predict 1-year non-relapse mortality (NRM) among older recipients of allogeneic transplantation: a prospective BMT-CTN study 1704. Blood. 2023;142(Supplement 1):109.CrossRef
18.
Bhatt VR, Gundabolu K, Koll T, Maness LJ. Initial therapy for acute myeloid leukemia in older patients: principles of care. Leuk Lymphoma. 2018;59(1):29–41.CrossRefPubMed
19.
Bhatt VR, Uy GL, Klepin HD. Determining treatment tolerance and fitness for intensive chemotherapy in older adults with AML: a call to action. Blood. 2024;143(6):483–7.CrossRefPubMed
20.
Bhatt VR, Wichman C, Koll TT, Fisher AL, Wildes TM, Berger A, et al. Longitudinal changes in cognitive and physical function and health-related quality of life in older adults with acute myeloid leukemia. J Geriatr Oncol. 2024;15(1):101676.CrossRefPubMed
21.
Dhakal P, Shostrom V, Al-Kadhimi ZS, Maness LJ, Gundabolu K, Bhatt VR. Usefulness of charlson comorbidity index to predict early mortality and overall survival in older patients with acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2020;20(12):804–12.CrossRefPubMedPubMedCentral
22.
Bhatt VR, Shostrom V, Holstein SA, Al-Kadhimi ZS, Maness LJ, Berger A, et al. Survival of older adults with newly diagnosed acute myeloid leukemia: effect of using multiagent versus single-agent chemotherapy. Clin Lymphoma Myeloma Leuk. 2020;20(5):e239–58.CrossRefPubMedPubMedCentral
23.
Klepin HD, Ritchie EK, Sanford BL, Marcucci G, Zhao W, Geyer SM, et al. Feasibility of geriatric assessment for older adults with acute myeloid leukemia (AML) receiving intensive chemotherapy on a cooperative group trial: CALGB 361006 (Alliance). J Clin Oncol. 2014;32(15_Suppl):7102.CrossRef
24.
25.
Bhatt VR, Ulrich AM, Uy GL, Stone RM, Stock W, Ojelabi MO, et al. Outcomes of older adults with AML treated in community versus academic centers: an analysis of alliance trials. JCO Oncol Pract. 2023;19(6):e877–91.CrossRefPubMedPubMedCentral
26.
Bhatt VR, Shostrom V, Giri S, Gundabolu K, Monirul Islam KM, Appelbaum FR, et al. Early mortality and overall survival of acute myeloid leukemia based on facility type. Am J Hematol. 2017;92(8):764–71.CrossRefPubMed
27.
Hurria A, Mohile S, Gajra A, Klepin H, Muss H, Chapman A, et al. Validation of a prediction tool for chemotherapy toxicity in older adults with cancer. J Clin Oncol. 2016;34(20):2366–71.CrossRefPubMedPubMedCentral
28.
Mohile SG, Dale W, Somerfield MR, Schonberg MA, Boyd CM, Burhenn PS, et al. Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology. J Clin Oncol. 2018;36(22):2326–47.CrossRefPubMedPubMedCentral
29.
Dale W, Klepin HD, Williams GR, Alibhai SMH, Bergerot C, Brintzenhofeszoc K, et al. Practical assessment and management of vulnerabilities in older patients receiving systemic cancer therapy: ASCO guideline update. J Clin Oncol. 2023;41(26):4293–312.CrossRefPubMed
30.
Diaz FC, Hamparsumian A, Loh KP, Verduzco-Aguirre H, Abdallah M, Williams GR, et al. Geriatric oncology: a 5-year strategic plan. Am Soc Clin Oncol Educ Book. 2024;44(3):e100044.CrossRefPubMedPubMedCentral
31.
Ginsburg GS, Picard RW, Friend SH. Key issues as wearable digital health technologies enter clinical care. N Engl J Med. 2024;390(12):1118–27.CrossRefPubMed
32.
Ehlers DK, Aguiñaga S, Cosman J, Severson J, Kramer AF, McAuley E. The effects of physical activity and fatigue on cognitive performance in breast cancer survivors. Breast Cancer Res Treat. 2017;165(3):699–707.CrossRefPubMed
33.
Anderson DE, Bhatt VR, Schmid K, Lunning M, Holstein SA, Rizzo M. Electrophysiological measure of impaired information processing in drivers with hematological malignancy. Transp Res Rec. 2018;2672(37):64–73.CrossRefPubMedPubMedCentral
34.
Anderson DE, Bhatt VR, Schmid K, Holstein SA, Lunning M, Berger AM, et al. Neurophysiological evidence of impaired attention and working memory in untreated hematologic cancer patients. Clin Neurophysiol. 2019;130(8):1243–52.CrossRefPubMedPubMedCentral
35.
Anderson DE, Kedar S, Bhatt VR, Schmid K, Holstein SA, Rizzo M. Neurophysiologic and ophthalmic markers of chemotherapy-related cognitive impairment in patients diagnosed with hematologic cancer: a feasibility study. J Neurol Sci. 2020;410:116644.CrossRefPubMed
36.
Cheng JJ, Tooze JA, Callahan KE, Pajewski NM, Pardee TS, Reed DR, et al. Assessment of an embedded primary care-derived electronic health record (EHR) frailty index (eFI) in older adults with acute myeloid leukemia. J Geriatr Oncol. 2023;14(7):101509.CrossRefPubMedPubMedCentral
37.
Klepin HD, Isom S, Callahan KE, Pajewski N, Topaloglu U, Wagner LI, et al. Frailty status determined by an electronic health record embedded frailty index and hospitalization risk among older adults following the initiation of cancer chemotherapy. J Clin Oncol. 2023;41(16_suppl):12010.CrossRef
38.
Shiwani T, Relton S, Evans R, Kale A, Heaven A, Clegg A, et al. New Horizons in artificial intelligence in the healthcare of older people. Age Ageing. 2023;52(12).
39.
Rosko AE, Elsaid M, Wall SA, Mims A, Woyach JA, Presley C, et al. Molecular biomarkers of aging to predict clinical frailty in newly diagnosed hematologic malignancy. Blood. 2023;142(Supplement 1):5164.CrossRef
40.
Ipson BR, Fletcher MB, Espinoza SE, Fisher AL. Identifying exosome-derived MicroRNAs as candidate biomarkers of frailty. J Frailty Aging. 2018;7(2):100–3.PubMedPubMedCentral
Metadaten
Titel
Developing a National Study That Integrates the Geriatric Assessment into the Care of Older Patients with Myeloid Malignancies
verfasst von
Vijaya Raj Bhatt
Publikationsdatum
11.09.2024
Verlag
Springer US
Erschienen in
Current Oncology Reports / Ausgabe 11/2024
Print ISSN: 1523-3790
Elektronische ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-024-01600-y

Weitere Artikel der Ausgabe 11/2024

Liver Cancer Etiology: Old Issues and New Perspectives

  • REVIEW

Risk Stratification, Screening and Treatment of BRAF/MEK Inhibitors-Associated Cardiotoxicity

  • REVIEW

Uterine-Conserving Treatment Options for Atypical Endometrial Hyperplasia and Early Endometrial Cancer

  • REVIEW

The Role of Cannabinoids in Advancing Cancer Treatment: Insights from Evidence-Based Medicine

  • Open Access
  • REVIEW

Prevention of Ovarian Cancer: Where are We Now and Where are We Going?

  • REVIEW

CAR T-cell Therapy for Central Nervous System Lymphoma

  • Review

Neu im Fachgebiet Onkologie

Welche Krebserkrankungen bei Zöliakie häufiger auftreten

Eine große Kohortenstudie hat den Zusammenhang zwischen Zöliakie und gastrointestinalen Krebserkrankungen und inflammatorischen Krankheiten untersucht. Neben gastrointestinalen Tumoren ist auch ein nicht solider Krebs häufiger.

Adjuvanter PD-L1-Hemmer verhindert Rezidive bei Hochrisiko-Urothelkarzinom

Sind Menschen mit muskelinvasivem Urothelkarzinom für die neoadjuvante platinbasierte Therapie nicht geeignet oder sprechen sie darauf nicht gut an, ist Pembrolizumab eine adjuvante Alternative: Die krankheitsfreie Lebenszeit wird dadurch mehr als verdoppelt.

Duale Checkpointhemmung gegen Melanome verlängert langfristig das Leben

Im Vergleich zu den Überlebenschancen vor der Einführung von Immuncheckpointhemmern (ICI) ist der Fortschritt durch eine ICI-Kombination mit unterschiedlichen Tagets bei fortgeschrittenem Melanom erstaunlich. Das belegen die finalen Ergebnisse der CheckMate-067-Studie und geben Betroffenen "Hoffnung auf Heilung".

Knochenmarktransplantat als Chance für ältere AML-Patienten

Lange Zeit ist die Transplantation von hämatopoetischen Stammzellen nur bei jüngeren Patienten mit akuter myeloischer Leukämie praktiziert worden. Inzwischen profitieren auch Ältere davon. Ergebnisse einer Studie unterstützen dieses Vorgehen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise